Cargando…

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

BACKGROUND: Gross cystic disease fluid protein 15 (GCDFP-15), which is regulated by the androgen receptor (AR), is a diagnostic marker for mammary differentiation in histopathology. We determined the expression of GCDFP-15 in breast cancer subtypes, its potential prognostic and predictive value, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darb-Esfahani, Silvia, von Minckwitz, Gunter, Denkert, Carsten, Ataseven, Beyhan, Högel, Bernhard, Mehta, Keyur, Kaltenecker, Gabriele, Rüdiger, Thomas, Pfitzner, Berit, Kittel, Kornelia, Fiedler, Bettina, Baumann, Klaus, Moll, Roland, Dietel, Manfred, Eidtmann, Holger, Thomssen, Christoph, Loibl, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122770/ https://www.ncbi.nlm.nih.gov/pubmed/25070172 http://dx.doi.org/10.1186/1471-2407-14-546

Ejemplares similares

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer
por: Darb-Esfahani, S, et al.
Publicado: (2012)

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer
por: Wenners, Antonia Sophie, et al.
Publicado: (2012)

Gross Cystic Disease Fluid Protein-15 (GCDFP-15) Expression Characterizes Breast Mucinous Carcinomas in Older Women
por: Kinoshita, Mayumi, et al.
Publicado: (2022)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Gross Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible Protein (PIP) as Functional Salivary Biomarker for Primary Sjögren’s Syndrome
por: Gallo, A, et al.
Publicado: (2013)

Immunoexpression of the GCDFP-15 Marker in Different Grades of Breast Carcinoma
por: Shirian, Faeze, et al.
Publicado: (2023)

Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers
por: Ahadi, Mahsa, et al.
Publicado: (2023)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013)

Androgen receptor increases and negative expression of GCDFP-15 in primary ductal adenocarcinoma of the lacrimal gland: a case description
por: Yang, Shideng, et al.
Publicado: (2023)

Comparison of GATA-3, Mammaglobin and GCDFP-15 Expression in Primary, Metastatic and Triple Negative Breast Carcinomas: An Indian Scenario
por: Rao, Meenakshi, et al.
Publicado: (2023)

GCDFP-15, AR, and Her-2 as biomarkers for primary ductal adenocarcinoma of the lacrimal gland: a Chinese case and literature review
por: Zhu, Miao-Miao, et al.
Publicado: (2015)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
por: von Minckwitz, Gunter, et al.
Publicado: (2008)

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
por: Lehmann, Annika, et al.
Publicado: (2009)

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs
por: Ataseven, Beyhan, et al.
Publicado: (2014)

15th International Workshop on Gross Properties of Nuclei and Nuclear Excitations
por: Feldmeier, Hans
Publicado: (1987)

Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator
por: Vlaicu, Philip, et al.
Publicado: (2013)

PTK 7 Is a Transforming Gene and Prognostic Marker for Breast Cancer and Nodal Metastasis Involvement
por: Gärtner, Silvia, et al.
Publicado: (2014)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

Full (15)N tracer accounting to revisit major assumptions of (15)N isotope pool dilution approaches for gross nitrogen mineralization
por: Braun, Judith, et al.
Publicado: (2017)

Classical pathology and mutational load of breast cancer – integration of two worlds
por: Budczies, Jan, et al.
Publicado: (2015)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

The Role of GDF15 as a Myomitokine
por: Johann, Kornelia, et al.
Publicado: (2021)

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
por: Budczies, Jan, et al.
Publicado: (2012)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Gross Cystic Disease Fluid Protein-15/Prolactin-Inducible Protein as a Biomarker for Keratoconus Disease
por: Priyadarsini, Shrestha, et al.
Publicado: (2014)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
por: Loibl, Sibylle, et al.
Publicado: (2011)

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
por: Braicu, Elena Ioana, et al.
Publicado: (2017)

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer
por: Poremba, Christopher, et al.
Publicado: (2014)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

Patterns in the relationship between life expectancy and gross domestic product in Russia in 2005–15: a cross-sectional analysis
por: Shkolnikov, Vladimir M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sgrofbsmjpm34qe1vmnoudil9k